2-甲基吡啶-3,5-二羧酸 | 89942-70-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-甲基吡啶-3,5-二羧酸
• 英文名称: 2-Methyl-pyridin-dicarbonsaeure-(3,5)
• 英文别名: 2-methyl-pyridine-3,5-dicarboxylic acid；2-Methyl-pyridin-3,5-dicarbonsaeure；2-Methylpyridine-3,5-dicarboxylic acid
• CAS: 89942-70-1
• 化学式: C₈H₇NO₄
• 分子量: 181.148
• InChiKey: UIGBPUBMNDUKPL-UHFFFAOYSA-N

物化性质

• 熔点：
  120-130 °C
• 沸点：
  444.4±45.0 °C(Predicted)
• 密度：
  1.460±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  87.5
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  2-甲基吡啶-3,5-二羧酸 在 乙醚 、 硫酸 、 氨 、 sodium amide 作用下， 生成 6-oxo-6H-quinolizin-1,3,7-tricarboxylic acid-7-ethyl ester-1,3-dimethyl ester
  参考文献：
  名称：

  Bohlmann et al., Chemische Berichte, 1955, vol. 88, p. 1831,1837

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 2-甲基吡啶-3,5-二羧酸
  参考文献：
  名称：

  Weber, Justus Liebigs Annalen der Chemie, 1887, vol. 241, p. 16

  摘要：

  DOI：

文献信息

• Dihydropyridines, processes and intermediates for their production, and pharmaceutical formulations containing them
  申请人：FISONS plc

  公开号：EP0174131A2

  公开（公告）日：1986-03-12

  There are described compounds of formula 1, in which R,, R2, R3, Rs and R6 are as defined in the specification and R4 is a phenyl group carrying 3 or 4 substituents or is an unsaturated 5 membered heterocyclic group containing a single hetero-atom selected from oxygen, sulphur or nitrogen, R4 being substituted by CF3, XR22, nitro, halogen, CN, alkyl C1 to 6, formyl dioxalanyl, -N(R23)COR24 -CONR25R26, or amino which is optionally substituted by phenylsulphonyl or by trifluoroacetyl, and R4 carries a substituent on the atom adjacent to the atom through which R4 is connected to the remainder of the molecule, R22 is phenyl or alkyl C1 to 6 optionally substituted by halogen, X is 0 or S(O)n, n is 0, 1 or 2, and R23, R24, R25 and R26, which may be the same or different, are each hydrogen or alkyl C1 to 6. There are also described methods for making the compounds, and their formulation and use as pharmaceuticals, eg for the treatment of cardiovascular conditions. There are further described compounds R4CHO which are useful in making compounds of formula I.

  所述化合物为式 1、 其中 R,、R2、R3、Rs 和 R6 如说明书中所定义，R4 是带有 3 或 4 个取代基的苯基，或者是含有一个选自氧、硫或氮的杂原子的不饱和 5 位杂环基团，R4 被 CF3、XR22、R4被 CF3、XR22、硝基、卤素、CN、C1-6 烷基、二噁烷甲酰基、-N(R23)COR24-CONR25R26 或任选被苯磺酰基或三氟乙酰基取代的氨基取代，且 R4 在与 R4 通过其与分子其余部分相连的原子相邻的原子上带有一个取代基、 R22 是苯基或任选被卤素取代的 C1 至 6 烷基、 X 是 0 或 S(O)n、 n 是 0、1 或 2，以及 R23、R24、R25 和 R26（可以相同或不同）各自为氢或 C1-6 烷基。 还描述了制造这些化合物的方法，以及它们作为药物的配制和使用，例如用于治疗心血管疾病。 此外，还描述了可用于制造式 I 化合物的 R4CHO 化合物。
• 7-(Pyridinyl)-/-alkyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid having antibacterial activity and preparation thereof
  申请人：STERLING DRUG INC.

  公开号：EP0179239A2

  公开（公告）日：1986-04-30

  1-Ethyt-6-ftuoro-1,4-dihydro-7-(2,6-dimethy)-4-pyridinyt)-4-oxo-3-quinolinecarboxylic acid or salt thereof, a novel compound useful highly potent antibacterial agent with a broad spectrum of anti-microbial activity, is prepared by nitrating the corresponding 6-desfluoro compound to produce the corresponding 6-nitro compound, reducing the latter compound to produce the corresponding 6-amino compound and converting the 6-amino via its diazonium salt to said 6-fluoro compound. Said novel acid is also prepared via intermediates prepared by heating 4-(2-fluorophenyl)-2,6-dimethyl-3,5-pyridinedicarboxylic acid to produce a mixture of 4-(2-fluorophenyl)-2,6-di-methylpyridine and 2,4-dimethyl-5H-[1]benzopyrano[3,4-c)pyridin-5-one, separating the components of said mixture and nitrating 4-(2-fluorophenyl)-2,6-dimethylpyridine to produce 4-(2-fluoro-5-nitrophenyl)-2,6-dimethylpyridine.

  1-乙基-6-氟-1,4-二氢-7-(2,6-二甲基)-4-吡啶)-4-氧代-3-喹啉羧酸或其盐是一种新型化合物，是一种具有广谱抗微生物活性的高效抗菌剂、其制备方法是：硝化相应的 6-去氟化合物，生成相应的 6-硝基化合物；还原后者，生成相应的 6-氨基化合物；然后通过重氮盐将 6-氨基化合物转化为所述 6-氟化合物。所述新型酸也可以通过加热 4-(2-氟苯基)-2,6-二甲基-3,5-吡啶二羧酸生成 4-(2-氟苯基)-2,6-二甲基吡啶和 2、4-(2-氟苯基)-2,6-二甲基吡啶和 2,4-二甲基-5H-[1]苯并吡喃并[3,4-c]吡啶-5-酮的混合物，分离所述混合物的组分并硝化 4-(2-氟苯基)-2,6-二甲基吡啶，生成 4-(2-氟-5-硝基苯基)-2,6-二甲基吡啶。
• Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions thereof
  申请人：FISONS plc

  公开号：EP0225175A2

  公开（公告）日：1987-06-10

  There are described compounds of Formula I, in which R₁, R₂, R₃ and R₄ are as defined in the specification, R₅ is alkyl optionally interrupted by an amide group and optionally substituted by halogen or by a carboxy or a heterocyclic group, X is -O-, -NR-, -S(O)m₁, or a bond, Z is hydrogen or together with R forms a bond, R is hydrogen, alkyl or together with Z forms a bond, R₆ is a 5 or 6 membered unsaturated nitrogen containing heterocyclic ring, optionally fused to a phenyl ring and optionally substituted by one or more of oxo, hydroxy, alkyl, -(CH₂)n₁NH₂, alkoxy, phenyl or -COOH, and when X is -NR- or -S(O)m₁-, R₆ may in addition be hydrogen or a group -CH₂CH₂NH₂, -CH₂CH₂-het. or NHC(=NH)NH₂, when X is -O-, R₆ may also be a group -NH₂, -C(=O) (CH₂)nNH₂, -CH₂CH₂NR₁₄R₁₅ or CH₂CH₂OCH₂CH₂NR₁₄R₁₅, when X is -NR-, -S(O)m₁-, or a bond, R₆ may also be hydrogen or a group -C(=NR₁₂)NHR₁₃, R₁₃ and R₁₄ may be hydrogen or alkyl, R₁₂ is hydrogen, alkylcarbonyl, nitrile or hydroxy, R₁₅ is hydrogen or a group R₁₁, m and m₁ are each 0, 1 or 2, n is 0 or 1, n₁ is an integer from 0 to 6 and pharmaceutically acceptable salts, esters, amides, analogues and protected derivatives thereof.

  所述化合物为式 I、 其中 R₁、R₂、R₃ 和 R₄ 如说明书中所定义、 R₅ 是任选被酰胺基打断并任选被卤素或羧基或杂环基取代的烷基、 X 是-O-、-NR-、-S(O)m₁ 或键、 Z 是氢，或与 R 形成键、 R 是氢、烷基或与 Z 共同形成键、 R₆ 是 5 或 6 个成员的不饱和含氮杂环，可选择与苯基环融合，并可选择被氧 化物、羟基、烷基、-(CH₂)n₁NH₂、烷氧基、苯基或-COOH 中的一个或多个取代、 当 X 为-NR-或-S(O)m₁-时，R₆ 还可以是氢或基团-CH₂CH₂NH₂、-CH₂CH₂-热或 NHC(=NH)NH₂ 、 当 X 为 -O- 时，R₆ 也可以是基团 -NH₂、-C(=O) (CH₂)nNH₂, -CH₂CH₂NR₁₄R₁₅ 或 CH₂CH₂OCH₂CH₂NR₁₄R₁₅、 当 X 为-NR-、-S(O)m₁- 或键时，R₆ 也可以是氢或基团-C(=NR₁₂)NHR₁₃、 R₁₃ 和 R₁₄ 可以是氢或烷基、 R₁₂ 是氢、烷基羰基、腈或羟基、 R₁₅ 是氢或基团 R₁₁、 m 和 m₁ 均为 0、1 或 2、 n 为 0 或 1、 n₁ 是 0 至 6 的整数 及其药学上可接受的盐、酯、酰胺、类似物和受保护的衍生物。
• THERAPEUTIC AGENT AND THERAPEUTIC METHOD RELATING TO 1,25D3-MARRS FOR NEUROLOGICAL DISEASE SUCH AS ALZHEIMER'S DISEASE& xA;
  申请人：Resilio Company Limited

  公开号：EP2946792A1

  公开（公告）日：2015-11-25

  A primary objective is to provide a drug for radical cure and a therapeutic method for diseases associated with axonal dysfunction (for example, Alzheimer's disease, dementia, Parkinson's disease, spinal cord injury, or brain contusion) based on the pathogenic mechanism thereof. Provided is a compound having a stimulating activity on 1,25D3-MARRS or a pharmaceutically acceptable salt thereof. Also provided is a technical idea relating to a pharmaceutical composition for disease treatment comprising a therapeutically effective amount thereof, a production method, a method for preventing or treating a disease, and a kit.

  其主要目的是根据轴突功能障碍的致病机制，提供一种根治与轴突功能障碍相关疾病（例如阿尔茨海默病、痴呆症、帕金森病、脊髓损伤或脑挫伤）的药物和治疗方法。 本发明提供了一种对 1,25D3-MARRS具有刺激活性的化合物或其药学上可接受的盐。还提供了一种技术构思，涉及一种包含治疗有效量的用于疾病治疗的药物组合物、一种生产方法、一种预防或治疗疾病的方法以及一种试剂盒。
• Corrosion inhibitor composition for magnesium or magnesium alloys
  申请人：Helmholtz-Zentrum Geesthacht Zentrum für Material-und Küstenforschung GmbH

  公开号：US10590343B2

  公开（公告）日：2020-03-17

  The present invention relates to novel corrosion inhibitor compositions for magnesium or magnesium alloys and to a process for inhibiting the corrosion of such metals using such compositions. The corrosion inhibitor composition for magnesium or magnesium alloys comprises at least one corrosion inhibiting compound which is capable of forming a complex with at least one of Fe(II), Fe(III), Cu(I), Cu(II) and Ni(II) ions, where the complex with at least one of Fe(II), Fe(III), Cu(I), Cu(II) and Ni(II) ions has a stability constant in aqueous solution at room temperature (about 21° C.) log K of greater than or equal to 3.5 wherein the corrosion inhibiting compound is selected from the group of pyridinedicarboxylic acids, and their salts or esters thereof.

  本发明涉及用于镁或镁合金的新型缓蚀剂组合物，以及使用此类组合物抑制此类金属腐蚀的工艺。用于镁或镁合金的缓蚀剂组合物包括至少一种能与 Fe(II)、Fe(III)、Cu(I)、Cu(II)和 Ni(II)离子中的至少一种形成络合物的缓蚀化合物，其中与 Fe(II)、Fe(III)、Cu(I)、Cu(II)和 Ni(II)离子中的至少一种形成的络合物在室温（约 21°C.其中缓蚀化合物选自吡啶二羧酸及其盐或酯类。